サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434124

自己免疫疾患治療薬市場：製品別、用途別-2024-2030年の世界予測

Autoimmune Disease Therapeutics Market by Product (Diagnostic Equipment, Drugs), Application (Localized Autoimmune Diseases, Systemic Autoimmune Diseases) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 197 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
自己免疫疾患治療薬市場：製品別、用途別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

自己免疫疾患治療薬市場規模は2023年に1,989億9,000万米ドルと推定され、2024年には2,145億4,000万米ドルに達し、CAGR 7.90%で2030年には3,390億米ドルに達すると予測されます。

自己免疫疾患治療薬の世界市場

主な市場の統計
基準年[2023］ 1,989億9,000万米ドル
予測年[2024] 2,145億4,000万米ドル
予測年 [2030] 3,390億米ドル
CAGR（%） 7.90%
自己免疫疾患治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは自己免疫疾患治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、自己免疫疾患治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-自己免疫疾患治療薬市場の市場規模および予測は？

2-自己免疫疾患治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-自己免疫疾患治療薬市場における技術動向と規制の枠組みは？

4-自己免疫疾患治療薬市場における主要ベンダーの市場シェアは？

5-自己免疫疾患治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で自己免疫疾患の有病率が増加
      • ヘルスケアインフラの急速な改善と患者の意識レベルの向上
      • いくつかの自己免疫診断検査を容易にするための検査室の自動化
    • 抑制要因
      • 高額な治療費と不確実な治療結果
    • 機会
      • 政府機関や非営利団体による資金提供の増加
      • 自己免疫疾患に対する標的療法の出現
    • 課題
      • 自己免疫疾患の免疫療法の副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 自己免疫疾患治療薬市場：製品別

  • 診断装置
  • 薬物
    • アミノサリチル酸塩または5-ASA
    • アントラリン
    • アボネックス
    • ベタセロン
    • カリシポトリエン
    • コパキソン
    • コルチコステロイド
    • 糖質コルチコイド
    • ヒドロキシクロロキン
    • メトトレキサート
    • 非ステロイド性抗炎症薬
    • レビフ

第7章 自己免疫疾患治療薬市場：用途別

  • 局所性自己免疫疾患
  • 全身性自己免疫疾患

第8章 南北アメリカの自己免疫疾患治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の自己免疫疾患治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの自己免疫疾患治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Beckman Coulter, Inc.
    • Bio-Rad Laboratories, Inc.
    • BioAgilytix Labs, LLC
    • bioMerieux S.A.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Exagen, Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services, Inc.
    • Lupin Limited
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi S.A.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech PLC
    • UCB S.A.
    • Werfen S.A.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AUTOIMMUNE DISEASE THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 9. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES OR 5-ASA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTHRALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AVONEX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BETASERON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CALICIPOTRIENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COPAXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTERIODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REBIF, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 152. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 153. AUTOIMMUNE DISEASE THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-030C42D3EDB8

[197 Pages Report] The Autoimmune Disease Therapeutics Market size was estimated at USD 198.99 billion in 2023 and expected to reach USD 214.54 billion in 2024, at a CAGR 7.90% to reach USD 339.00 billion by 2030.

Global Autoimmune Disease Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 198.99 billion
Estimated Year [2024] USD 214.54 billion
Forecast Year [2030] USD 339.00 billion
CAGR (%) 7.90%
Autoimmune Disease Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Autoimmune Disease Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Autoimmune Disease Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, bioMerieux S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Exagen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, UCB S.A., and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Diagnostic Equipment
    • Drugs
      • Aminosalicylates or 5-ASA
      • Anthralin
      • Avonex
      • Betaseron
      • Calicipotriene
      • Copaxone
      • Corticosteriods
      • Glucocorticoids
      • Hydroxychloroquine
      • Methotrexate
      • Non-steroidal Anti-inflammatory Drugs
      • Rebif
  • Application
    • Localized Autoimmune Diseases
    • Systemic Autoimmune Diseases
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Autoimmune Disease Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Autoimmune Disease Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Autoimmune Disease Therapeutics Market?

4. What is the market share of the leading vendors in the Autoimmune Disease Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Autoimmune Disease Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Autoimmune Disease Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of autoimmune diseases across the globe
      • 5.1.1.2. Rapidly improvement in healthcare infrastructure coupled with rising patient awareness levels
      • 5.1.1.3. Automation of laboratories to ease several autoimmune diagnostic tests
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and uncertain outcomes of the treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing funding by government associations and non-profit organizations
      • 5.1.3.2. Emergence of target therapies for autoimmune disease
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of autoimmune diseases immunotherapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Autoimmune Disease Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnostic Equipment
  • 6.3. Drugs
    • 6.4.1. Aminosalicylates or 5-ASA
    • 6.4.2. Anthralin
    • 6.4.3. Avonex
    • 6.4.4. Betaseron
    • 6.4.5. Calicipotriene
    • 6.4.6. Copaxone
    • 6.4.7. Corticosteriods
    • 6.4.8. Glucocorticoids
    • 6.4.9. Hydroxychloroquine
    • 6.4.10. Methotrexate
    • 6.4.11. Non-steroidal Anti-inflammatory Drugs
    • 6.4.12. Rebif

7. Autoimmune Disease Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Localized Autoimmune Diseases
  • 7.3. Systemic Autoimmune Diseases

8. Americas Autoimmune Disease Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Autoimmune Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Autoimmune Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. AbbVie Inc.
    • 12.1.3. Amgen Inc.
    • 12.1.4. AstraZeneca PLC
    • 12.1.5. Beckman Coulter, Inc.
    • 12.1.6. Bio-Rad Laboratories, Inc.
    • 12.1.7. BioAgilytix Labs, LLC
    • 12.1.8. bioMerieux S.A.
    • 12.1.9. Bristol-Myers Squibb Company
    • 12.1.10. Eli Lilly and Company
    • 12.1.11. Exagen, Inc.
    • 12.1.12. F. Hoffmann-La Roche Ltd.
    • 12.1.13. GlaxoSmithKline PLC
    • 12.1.14. Johnson & Johnson Services, Inc.
    • 12.1.15. Lupin Limited
    • 12.1.16. Merck & Co., Inc.
    • 12.1.17. Novartis AG
    • 12.1.18. Pfizer, Inc.
    • 12.1.19. Sanofi S.A.
    • 12.1.20. Siemens Healthineers AG
    • 12.1.21. Thermo Fisher Scientific Inc.
    • 12.1.22. Trinity Biotech PLC
    • 12.1.23. UCB S.A.
    • 12.1.24. Werfen S.A.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing